GeneralConnection.com ➔ Dictionary
Dictionary Search

infliximab

Synonyms

Noun

1. Remicade

2. anti-TNF compound

Usage
Fulminant Tetraplegia in a Patient on Infliximab: A Case of Masked Cervical Spinal Epidural Abscess Presenting With Dysphagia - Cureus
Earlier Infliximab Shortens Hospital Stay in Severe Ulcerative Colitis - EMJ
Subcutaneous Infliximab for CD by Location - Docwire News
Effectiveness of Infliximab for Refractory Nonischemic Cerebral Enhancing Foreign-Body Granulomatous Lesions After Endovascular Therapy - Neurology® Journals
Pharmacokinetic Model Selection for Personalized Infliximab Dosing in IBD - Wiley
Major Industry Participants Consolidating Their Presence - openPR.com
‘Pleasantly surprised’: Subcutaneous infliximab effective, regardless of Crohn’s location - Healio
Celltrion Secures First Approval of Infliximab IV Liquid Formulation - Pearce IP
Comparison of endoscopic healing and durability between combination therapy with infliximab and azathioprine versus infliximab monotherapy in pediatric Crohn’s disease - Nature
Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal - PR Newswire
Infliximab, Upadacitinib Offer Rapid Relief in Ulcerative Colitis - Medscape
Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial - The Lancet
The Biosimilar Shift: Trending Infliximab Biosimilar Utilization and Associated Cost Savings for Commercial Insurance - AJMC
Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111 - Center for Biosimilars
New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday - BioSpace
Infliximab and Adalimumab Biosimilars Maintain Comparable Safety, Efficacy, Immunogenicity in IBD - Pharmacy Times
Early Colectomy After Infliximab in Ulcerative Colitis Linked to C. difficile Infection - Docwire News
Accelerated infliximab induction reduces long-term odds of colectomy in ulcerative colitis - Healio
Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence - Center for Biosimilars
Case Report: Facial Malassezia folliculitis following infliximab treatment in Crohn's disease - Frontiers
Implications of the First Liquid IV Infliximab Biosimilar - BioPharm International
Study Shows Infliximab Biosimilar is Safe in Patients Undergoing RA Treatment - Pharmacy Times
Celltrion Launches IV Formulation of Biosimilar Infliximab in Europe - Pearce IP
Celltrion launches liquid formulation of Remsima IV in Europe to strengthen infliximab market leadership - koreabiomed.com
Association of the TNFRSF1B -rs1061622 variant with nonresponse to infliximab in ulcerative colitis - Nature
Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients - Frontiers
Celltrion Presents Positive Real-World Data on Switching from intravenous (IV) to subcutaneous (SC) infliximab at UEG Week 2025 Meet the Expert sessions - Business Wire
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab - Business Wire
Case Report: Infliximab for hydroxychloroquine-induced AGEP with IL17A and IL36RN mutations: a case report and management considerations - Frontiers
Case Studies Highlight Link Between Crohn’s Disease Treatment and IgAN - Docwire News
Successful Treatment of Pediatric Neurosarcoidosis With Corticosteroids, Infliximab, and Methotrexate - ScienceDirect.com
Infliximab treatment for autoimmune hepatitis - Clínica FEHV
Bastian Schilling: Infliximab for Steroid-Refractory irHepatitis - Efficacy and Safety Demonstrated - Oncodaily
Pfizer’s IV Infliximab Biosimilar Approved in NZ - Pearce IP
Celltrion enters Japanese market for arthritis treatments with new biosimilar - The Korea Times
Infliximab Biosimilar Initiation Has Increased in Pediatric IBD, Study Finds - Pharmacy Times
PET/CT supports use of infliximab for cardiac sarcoidosis - AuntMinnie
Precision-Medicine Approach Improves IBD Infliximab Outcomes - Medscape
Celltrion Launches Abtozma in Japan - Businesskorea
Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease - NEJM Evidence
Infliximab versus Cyclophosphamide for Severe Behçet’s Syndrome - NEJM Evidence
Study Confirms Comparable Safety of Infliximab Biosimilar in Rheumatoid Arthritis Treatment - geneonline.com
FDA Approves First Subcutaneous Infliximab Product - Center for Biosimilars
Celltrion’s Remsima SC First to LATAM Market - Pearce IP
Tracing the historical foundations of infliximab in Crohn’s disease treatment: a cited reference analysis - Frontiers
Zymfentra, a Subcutaneous Formulation of Infliximab, Approved for IBD - Medical Professionals Reference
Celltrion's infliximab subcutaneous injection (SC) formulation treatment "Zimpentra" has proven the - 매일경제
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration | Scientific Reports - Nature
Celltrion’s Remsima cements status as S.Korea’s blockbuster global medicine - KED Global
Subcutaneous Infliximab Therapy Efficacious for Inflammatory Bowel Disease - Gastroenterology Advisor
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials - The Lancet
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial - The Lancet
Infliximab treatment in pathology-confirmed neurosarcoidosis - Neurology® Journals
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease - The New England Journal of Medicine
Celltrion Launches Trastuzumab and Infliximab Biosimilars in Vietnam - Pearce IP
Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis - Nature
Are Live Vaccines Safe for Infants Exposed to Infliximab During Parent’s IBD Treatment? - Gastroenterology Advisor
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome - Nature
FDA Approves First Subcutaneous Infliximab for Maintenance Therapy in UC and Crohn Disease - HCPLive
Additional Dose of IVIG Provides Positive Therapeutic Effect in Patients With Infliximab-Refractory Kawasaki Disease - Pharmacy Times
Weight Gain on Infliximab Tied to Sex, Crohn Disease, and Disease Severity - Gastroenterology Advisor
ZYMFENTRA™(infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab, now commercially available in the U.S. - PR Newswire
Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease - Frontiers
Opacity over live vaccines in infants exposed to infliximab - The Lancet
Biosimilar vs Bio-Originator Infliximab and Etanercept Show Similar Infection Rates - Rheumatology Advisor
Vedolizumab Beats Infliximab as Second-Line Therapy for Ulcerative Colitis - Medscape
Early Crohn's treatment 'could save NHS millions' - BBC
Oxford patients with sarcoidosis in lungs given new drug - BBC
Timing of Infliximab Infusion Prior to Surgery and Post-Operative Infections - Rheumatology Advisor
Initial dose of infliximab 5 mg/kg ‘should be adequate’ in most cases of acute severe UC - Healio
Infliximab Cost - News-Medical
Aggressive Infliximab Dosing Shows No Added Benefit in Acute Severe Ulcerative Colitis - Medscape
Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matching - Nature
Treating IBD During Pregnancy - Johns Hopkins Medicine
Celltrion announced on the 19th that its infliximab subcutaneous injection (SC) formulation treatmen.. - 매일경제
Infliximab Improves Ulcerative Colitis, Crohn's Disease Regardless of Immunosuppressants - HCPLive
Monocytes from infliximab-resistant patients with Crohn’s disease exhibit a disordered cytokine profile - Nature
Anti-NMDAR encephalitis in Crohn’s disease undergoing long-term infliximab treatment: A case report - Frontiers
A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet’s syndrome - Nature
Pericardial Effusion due to Infliximab Therapy for Ulcerative Colitis - Wiley Online Library
Detecting early safety signals of infliximab using machine learning algorithms in the Korea adverse event reporting system - Nature
Switch to Subcutaneous Infliximab Maintains Clinical Remission in Patients with IBD - HCPLive
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis - The New England Journal of Medicine
No Difference in Pediatric Growth Rates with Infliximab Biosimilar vs Reference Agent - HCPLive
Posters Demonstrate Switching Safety Between Originator, Biosimilar Infliximab in IBD - Center for Biosimilars
SC Infliximab Superior to IV Dosage in Patients With Crohn Disease, Ulcerative Colitis - Center for Biosimilars
FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union - Biogen
Phase 3 Trials Find Subcutaneous Infliximab CT-P13 Superior to Placebo in IBD - Center for Biosimilars
Dual therapy with infliximab and IVIG in children with multi-system inflammatory syndrome - 2 Minute Medicine
Infliximab is a plausible alternative for neurologic complications of Behçet disease - Neurology® Journals
Infliximab bests cyclophosphamide as first-line treatment of severe Behçet’s syndrome - Healio
Case Report: Development of medication-related osteonecrosis of the jaw in a patient on long-term infliximab therapy - Frontiers
Subcutaneous Infliximab or Vedolizumab maintenance IBD Upadacitinib Crohn's disease Miguel Regueiro - Gastroenterology & Endoscopy News
The impact of medication belief on adherence to infliximab in patients with Crohn’s disease - Frontiers
When Patients Develop Antibodies to TNF Inhibitors - MedCentral
Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar | Scientific Reports - Nature
Infliximab for the treatment of ocular cicatricial pemphigoid, a Preliminary Report - ARVO Journals
Infliximab, Ustekinumab, and Tofacitinib Effective in Ulcerative Colitis - Gastroenterology Advisor
The Impact of Intermediate Antidrug Antibodies to Infliximab and Adalimumab on Clinical Outcomes in Patients with Crohn’s Disease or Ulcerative Colitis - EMJ
Comparable Pregnancy and Infant Milestones With Infliximab Biosimilars vs Originator in IBD - Center for Biosimilars
Foreign Language Equivalents
Foreign Language Equivalents of 'infliximab'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
inflizimab,   inflixmiab,   infilximab,   inflixiimab,   influximab,   infliximsb,   inffliximab,   infliximabb,   inflixximab,   innfliximab,   inflixi,ab,   nifliximab,   inflxiimab,   infkiximab,   infliximan,   infliximmab,   inflixmab,   ifliximab,   infliximaab,   indliximab,   iinfliximab,   inliximab,   ingliximab,   inflliximab,   inflixima,   inf;iximab,   infliximba,   onfliximab,   ifnliximab,   infiximab,   inflicimab,   infloximab,   inlfiximab,   imfliximab,   inflixiab,   ibfliximab,   unfliximab,   infliximav,   infliimab,   inflixinab,   infliximb,   inflixomab,   inflximab,   inflixumab,   nfliximab,   infliixmab,   inflixiamb,   infliiximab
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z